Official endorses policy while owning beneficiary stock

A senior health official publicly promoted a regulatory change easing warnings on a medical therapy while retaining stock and options in a private company that stands to profit. The paperwork shows at least $115,000 in stock and uncertified disclosure forms, and the private firm expanded nationally soon after the policy was announced. — This pattern sharpens debates about ethics enforcement, recusal rules, and how public statements by regulators can create market windfalls for related private firms.